Vincerx Pharma, Inc. — Cyborg Score 1/10

Strategic Profile

The company's lead product candidate, pacritinib—an oral JAK2/IRAK1 inhibitor—was in-licensed from CTI BioPharma Corp. and was being evaluated for the treatment of myelofibrosis, particularly in patients with severe thrombocytopenia. Vincerx has announced its intention to delist from Nasdaq and deregister with the SEC, with plans to file a Form 25 for delisting in late April 2025.

Cyborg Score Rationale

The company is in active dissolution with a stock price of $0.0127 as of April 2026 and a market cap under $1 million. The company's board determined that dissolving, liquidating, and winding up operations is in the best interest of stockholders, and management has been authorized to begin wind-down activities and explore asset monetization opportunities.

Top Insights

• (April 2025) Nasdaq delisting notice issued due to non-compliance with minimum bid price requirement
• (April 2025) Form 25 filed for delisting; company terminated merger agreement with QumulusAI
• (April 2026) Stock trading at $0.0127 per share with minimal market capitalization
• Clinical oncology pipeline in pacritinib (JAK2/IRAK1 inhibitor) abandoned as company winds down

Recent Developments

• (April 2025) Nasdaq delisting initiated; company began liquidation planning
• (April 2025) Terminated non-binding merger agreement with QumulusAI
• (April 2026) Stock price at $0.0127; company in active wind-down and asset monetization phase

Open the full interactive Vincerx Pharma, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.